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Abstract
Desmopressin is a synthetic analogue of the natural antidiuretic hormone arginine vasopressin. Over the years, it has been 
clinically used to manage nocturnal polyuria in children with enuresis. Various pharmaceutical formulations of desmopres-
sin have been commercialized for this indication—nasal spray, nasal drops, oral tablet and oral lyophilizate. Despite the fact 
that desmopressin is a frequently prescribed drug in children, its use and posology is based on limited pediatric data. This 
review provides an overview of the current pediatric pharmacological data related to the different desmopressin formulations, 
including their pharmacokinetics, pharmacodynamics and adverse events. Regarding the pharmacokinetics, a profound food 
effect on the oral bioavailability was demonstrated as well as different plasma concentration–time profiles (double absorption 
peak) of the desmopressin lyophilizate between adults and children. Literature about maturational differences in distribution, 
metabolism and excretion of desmopressin is rather limited. Regarding the pharmacodynamics, formulation/dose/food effect 
and predictors of response were evaluated. The lyophilizate is the preferred formulation, but the claimed bioequivalence in 
adults (200 µg tablet and 120 µg lyophilizate), could not be readily extrapolated to children. Prescribing the standard flat-dose 
regimen to the entire pediatric population might be insufficient to attain response to desmopressin treatment, whereby dos-
ing schemes based on age and weight were proposed. Moreover, response to desmopressin is variable, whereby complete-, 
partial- and non-responders are reported. Different reasons were enumerated that might explain the difference in response 
rate to desmopressin observed: different pathophysiological mechanisms, bladder capacity and other predictive factors (i.e. 
breast feeding, familial history, compliance, sex, etc.). Also, the relapse rate of desmopressin treatment was high, render-
ing it necessary to use a pragmatic approach for the treatment of enuresis, whereby careful consideration of the position 
of desmopressin within this treatment is required. Regarding the safety of the different desmopressin formulations, the use 
of desmopressin was generally considered safe, but additional measures should be taken to prevent severe hyponatremia. 
To conclude the review, to date, major knowledge gaps in pediatric pharmacological aspects of the different desmopressin 
formulations still remain. Additional information should be collected about the clinical relevance of the double absorption 
peak, the food effect, the bioequivalence/therapeutic equivalence, the pediatric adapted dosing regimens, the study endpoints 
and the difference between performing studies at daytime or at nighttime. To fill in these gaps, additional well designed 
pharmacokinetic and pharmacodynamic studies in children should be performed.
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1 Introduction
The synthetic vasopressin analogue desmopressin has been 
used clinically for > 40 years in the treatment of enuresis 
(high, diluted urine output overnight) and central diabe-
tes insipidus (CDI) [1–4]. In very high doses, desmopres-
sin is also used to treat the congenital bleeding disorders, 
hemophilia A and von Willebrand disease, since it increases 
the von Willebrand factor, coagulation factor VIII and tissue 
plasminogen activator [5, 6]. Moreover, desmopressin has 
proven suitable to diagnose renal concentrating capacity (i.e. 
patients with CDI, urinary tract infections and suspected 
kidney damage) [7, 8]. The current review focusses on the 
use of desmopressin in children with enuresis, and does not 
discuss the use in diagnostic testing, nor in the treatment of 
children with CDI or congenital bleeding disorders.
Over the years, various pharmaceutical formulations of 
the antidiuretic desmopressin have been commercialized: 
nasal spray (since 1972), nasal drops (since 1972), oral tablet 
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Key Points 
The current review summarizes the available literature 
concerning the pharmacology of desmopressin in chil-
dren with enuresis.
Despite the fact that desmopressin has been available 
for more than 40 years, there remains a need for addi-
tional pharmacokinetic and pharmacodynamic studies in 
children.
To date, multiple research questions remain unanswered 
in the pediatric population: is there a double absorption 
peak? Is there a food effect? Is there bioequivalence/
therapeutic equivalence? What is the optimal dosing 
regimen?
formulations, despite the limited efficacy and safety data 
for these formulations in the pediatric population (i.e. lack 
of pharmacokinetic (PK) data of oral desmopressin, lack of 
bioequivalence studies, lack of availability of size-dependent 
dosing strategies, lack of safety studies). Over the years, 
additional research was performed to fill in some knowl-
edge gaps [13–17, Dossche et al., submitted], but additional 
research is still required. Therefore, the aim of the current 
review is to provide an overview of the pediatric pharma-
cological data of the different desmopressin formulations, 
including their therapeutic use, PK, pharmacodynamics 
(PD) and safety. This overview contributes to the identifica-
tion of which information is already available and which 
information is still missing to enable adapted desmopressin 
treatment strategies for children.
2  Structure and Physicochemical Properties
Desmopressin (1-desamino-8-d-arginine vasopressin, 
dDAVP), is a synthetic analogue of the natural antidiuretic 
hormone arginine vasopressin (AVP). Desmopressin was 
first synthetized in 1967 by deamination of the cysteine 
residue (prolonged activity due to a lipophilic N-termi-
nal) and replacing the l-arginine configuration with the 
d-arginine configuration (reduced vasopressor activity due 
to changes in polarization of the molecule) (Fig. 1) [18]. 
The molecular formula of the nonapeptide desmopressin 
is  C46H64N14O12S2, with a molecular mass of 1069.224 g/
mol. The active ingredient of the different formulations is 
desmopressin acetate. Desmopressin has a negative clog P 
(− 7.711), which demonstrates the extreme hydrophilicity 
of this drug [19]. Desmopressin is a base with a pKa of 11.8 
(strongest base).
Fig. 1  Chemical structure of vasopressin (a) and desmopressin (b). Deamination (green) and l-arginine versus d-arginine configuration (orange) 
(made in Chemdraw 16®, PerkinElmer, USA)
(since 1987) and oral lyophilizate (since 2005) [9]. All for-
mulations have proven efficacy for children with enuresis, 
that is, resulted in a reduction of the number of wet nights. 
The conventional route of administration of desmopressin 
in adults and children used to be intranasal (IN) (drops or 
spray), since this route bypasses the gastrointestinal tract, 
leading to an increase in absolute bioavailability and hence 
a lower dose. However, in 2007, the Food and Drug Admin-
istration (FDA) announced a post-marketing drug safety 
warning about the use of nasal sprays in children, which 
was based on a limited number of case reports demonstrat-
ing that IN administration of desmopressin could potentially 
lead to severe hyponatremia and seizures [10]. These adverse 
events could be attributed to the variability in absorption 
and unintentional overdosing when using the nasal spray 
[11, 12]. Consequently, the use of IN formulations is no 
longer approved for treating enuresis in children in the 
United States of America (US) and most of the European 
countries. The latter required a definitive switch to oral 
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3  Mode of Action
Desmopressin is mainly designed to treat nocturnal polyu-
ria with increased free water diuresis by acting on the  V2 
vasopressin receptors of the collecting ducts [20–22]. The 
drug binds to the  V2 receptor in the basolateral membrane 
of the collecting duct, stimulating the  Gs-coupled protein to 
activate adenylate cyclase, leading to the formation of cyclic 
adenosine monophosphate (cAMP) from adenosine triphos-
phate (ATP). cAMP binds to protein kinase A, activating 
the phosphorylation cascade, whereby the exocytosis of 
aquaporin-2 water channels from cytoplasmic aquaporin-2 
water channel-containing vesicles towards the apical mem-
brane of the collecting ducts is stimulated. Osmotic pressure 
(osmotic gradient established by NaCl and urea) between the 
lumen and the interstitium facilitates the water reabsorption 
through the water channels, resulting in urine concentration 
(Fig. 2) [23]. This almost exclusive  V2 receptor targeting 
results in antidiuresis by increased urinary concentration, 
without having a vasoconstrictor effect on the blood vessels.
4  Therapeutic Use in Nocturnal Enuresis 
in Children
According to the International Children’s Continence Soci-
ety (ICCS), enuresis or bedwetting means micturition dur-
ing sleep in a child of at least 5 years, the age at which 
bladder control should have been achieved [25]. Enuresis 
is subdivided into monosymptomatic (MNE) and non-
monosymptomatic enuresis (NMNE), whereby for the lat-
ter, enuresis associated with symptoms of the lower urinary 
tract including daytime incontinence is observed [26]. The 
prevalence of enuresis is 12–25% in 5-year-old children, 
6–8% in 8-year-old children, 2–3% in 12-year-old children 
and 0.5–1.7% in adulthood [27, 28]. The prevalence rate is 
higher in boys than in girls (2:1) [29], for which the reason 
is unclear up to now. The cure rate is defined as the achieve-
ment of complete dryness without arousal [30]. The annual 
spontaneous cure rate of enuresis is 14% in 5- to 9-year-
old children, 16% in 10- to 14-year-old children and 16% 
in 15- to 19-year-old adolescents [30]. Not all patients with 
enuresis will cure spontaneously, and persisting enuresis is 
observed in 0.5–1.7% of the adolescents [11, 31]. Enuresis 
can potentially lead to distress, which has an impact on the 
child’s self-esteem, social life, quality of sleep and school 
performance [32]. Both the impact on the well-being of the 
child as well as the persistence of enuresis in adolescents 
necessitates an effective therapy [33]. This therapy requires 
appropriate diagnosis of the enuresis type by proper screen-
ing of the patient, followed by administration and evaluation 
of the prescribed therapy [34]. Desmopressin and enuresis 
alarm are the only level 1 evidence and grade A first-line 
enuresis treatments recommended by the International Con-
sultation on Incontinence [35].
Antidiuretic doses of the different formulations are listed 
in Table 1. For enuresis, it is recommended to administer 
oral desmopressin 1 h prior to bedtime, preferably without 
simultaneous food intake [15, 36, 37]. 2 weeks after start-
ing desmopressin therapy, dosages should be individually 
adapted, preferably according to anti-enuretic and anti-diu-
retic effects. In enuresis, the therapy should be re-evaluated 
every 3 months (treatment withdrawn for at least 1 week) to 
monitor if further treatment is required [38]. A structured 
withdrawal is required when discontinuing desmopressin 
treatment, to evaluate if enuresis reoccurs. This structured 
withdrawal is preferred over sudden termination, since it 
results in an increasing success rate and a decreasing relapse 
rate [39, 40]. Moreover, dose-dependent withdrawal (lower-
ing the dose) results in less wet incidents in comparison with 
time-dependent withdrawal (increasing time between doses) 
and is therefore the preferred approach [41, 42].
4.1  Desmopressin and Alarm Therapy
Several authors evaluated if combination therapy could be 
more beneficial than desmopressin monotherapy. Evaluating 
different types of therapy is necessary, however the results 
of these studies should be carefully interpreted since the 
lack of subtyping of enuresis might result in confounded 
results. Ideally, to assess these therapies, only carefully com-
pared patients can be used as their own controls. Moreover, 
Fig. 2  Mechanism of action of desmopressin. 1: AVP binds to recep-
tor, 2: receptor activates second messenger system, 3: cAMP binds 
PK, 4: exocytosis aquaporin channels, 5: water absorption. AC ade-
nylate cyclase, AQP2 aquaporin water channel AQP2WCV aquaporin 
2 water channel-containing vesicles, ATP adenosine triphosphate, 
AVP arginine vasopressin, cAMP cyclic adenosine monophosphate, 
PK protein kinase A, V2R  V2 vasopressin receptor (adapted from 
[24])
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definitions about response rate of different therapies should 
be carefully interpreted, since for desmopressin therapy the 
decrease of number of dry nights is often used, whereas 
for alarm therapy the percentage of nights the child arouses 
for urination is determined [30]. Perrin et al. [43] and Peng 
et al. [44] performed a systematic literature review on alarm 
versus desmopressin monotherapy in children with MNE, 
showing that alarm therapy was preferred due to the lower 
relapse rate. However, the latter is only applicable to moti-
vated children, since a much higher dropout rate was noted 
with the alarm [45, 46]. The latter conclusions were con-
firmed by a network meta-analysis performed by Song et al. 
[47].
4.2  Desmopressin and Other Drugs
Lee et  al. [48] evaluated the efficacy of desmopressin 
monotherapy versus desmopressin combined with oxybu-
tynin (anticholinergic) and versus imipramine (tricyclic 
antidepressant) monotherapy in children with enuresis 
(5–15 years). The authors concluded that the efficacy of 
combination therapy was higher in comparison with both 
monotherapies. The latter was inconsistent with the results 
found by Naitoh et al. [49], where no significant differences 
between alarm monotherapy, desmopressin or imipramine 
and alarm combination therapy were observed. In a pilot 
study, De Guchtenaere et al. [50] demonstrated that addi-
tion of early morning furosemide (diuretic) significantly 
lowered nocturnal diuresis rates in children with MNE 
resistant to desmopressin. Alloussi et al. [51] evaluated the 
combination of propiverine (antimuscarinic) and desmopres-
sin in children with bedwetting. This combination therapy 
was highly effective, but a further decrease of the relapse 
rate (21.5%) and fine tuning of dosing regimens was still 
required. This combination was then optimized by Jab-
bour et al. [52], whereby the relapse rate decreased to 13%. 
However, it should be noted that the reported relapse rates 
might be an overestimation of the real-life situation, since 
only children who were unresponsive to monotherapy were 
included. Park et al. [53] demonstrated that a combination 
of desmopressin and an anticholinergic drug (oxybutynin, 
tolterodine [antimuscarinic], propiverine [antimuscarinic]) 
resulted in a more effective and faster response than desmo-
pressin monotherapy. A possible role for the combination 
of desmopressin and oxybutynin in desmopressin mono-
therapy non-responders was confirmed by Radvanska et al. 
[54]. Azarfar et al. [55] demonstrated that the combination 
of desmopressin and tolterodine had a lower relapse rate 
than desmopressin and oxybutynin combination therapy. 
Kamperis et al. [56] administered either a combination of 
indomethacin (non-steroidal anti-inflammatory drug) and 
desmopressin, or a placebo and desmopressin, to children 
with MNE and desmopressin-resistant nocturnal polyuria. 
The authors concluded that there was an added effect of 
indomethacin to desmopressin therapy, leading to a greater 
reduction in nocturnal urinary output. However, the number 
of wet nights was not significantly different between combi-
nation and monotherapy.
5  Pharmacokinetics
The nasal route of administration is traditionally preferred 
for peptide drug delivery, since the relatively large surface 
area, thin epithelium and rich vascularization facilitate the 
absorption of these peptides. However, higher inter- and 
intra-subject variability in PK was observed following IN 
administration [57]. Subsequently, alternative routes of 
administration, such as the oral lyophilizate, were explored. 
Table 2 gives an overview of the PK parameter values of 
desmopressin administered via different formulations in 
humans. Only five papers described PK studies performed in 
the pediatric subpopulation for treatment of enuresis (high-
lighted in Table 2) [13–17, 58, Dossche et al., submitted].
Table 1  Antidiuretic doses of different desmopressin formulations ( adapted from SPC Minirin® Ferring)
CDI central diabetes insipidus, IM intramuscular, IV intravenous, PO per oral, SC subcutaneous
Formulation Indication Age Dose Dosing interval
Lyophilizate Enuresis Adult/child (> 5 years) 120–240 µg 1 per day, evening
CDI Adult/child (> 5 years) 60–120 µg 3 per day
Nocturia Adult/child (> 5 years) 60–240 µg 1 per day, evening
Nasal spray CDI Adult 10–20 µg 2 per day
Nasal drops CDI Adult 10–20 µg 2 per day
IV/IM/SC injection CDI Adult 1–4 µg 1 per day
CDI Child 0.4 µg 1 per day
PO tablet Enuresis Adult/child (> 5 years) 200–400 µg 1 per day, evening
CDI Adult/child (> 5 years) 100–200 µg 3 per day
Nocturia Adult/child (> 5 years) 100–400 µg 1 per day, evening
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5.1  Absorption
Oral desmopressin is absorbed relative rapidly via a para-
cellular route in the duodenum and the proximal jejunum, 
reaching maximal plasma concentrations (Cmax) between 
0.6 and 1.5 h after administration (Tmax) in healthy male 
adults [59, 60]. Overall, the oral bioavailability in healthy 
adults is extremely low (0.08–0.16%), since desmopressin 
is enzymatically degraded in the lumen of the gastrointes-
tinal tract and the high molecular weight of desmopressin 
makes the paracellular absorption inefficient [19]. Moreover, 
absorption via a transcellular route seems less likely, due to 
the negative clog P (− 7.711) observed for desmopressin. 
Osterberg et al. [13] stated that the oral absorption process 
of desmopressin might be different for children (enuresis, 
ages 6–13 years), since the mean transit time was signifi-
cantly different in comparison with adults (children: 0.21 h, 
adults: 0.48 h). This observation could be attributed to a 
maturational change in absorptive surfaces, gastric empty-
ing and/or intestinal motility. The bioavailability following 
IN administration in healthy adults is better (3–5%) when 
compared with oral (PO) administration [61].
Gasthuys et al. [16] evaluated the PK of desmopressin 
lyophilizate in growing piglets (Belgian Landrace × large 
white; 8 days, 4 weeks, 7 weeks, 6 months of age) using 
population PK modeling. This was the first study demon-
strating a dual sequential absorption process, with a dou-
ble peak present in the absorption phase, probably attrib-
uted to transmucosal absorption in the oral cavity and the 
small intestine. This observation was also hypothesized by 
Michelet et al. [62], who found a discrepancy when linking 
their previously published PK model [15] to their PD param-
eters in children. The authors observed a significant effect 
of the formulation on the  IC50 (half maximal inhibitory con-
centration), which is physiologically implausible since only 
at the PK side a formulation effect is expected. A possible 
explanation was that the model was not able to capture the 
absorption part due to the sparse sampling design applied in 
the human pediatric studies, resulting in a mismatch between 
the PK and the PD models. Two possible hypotheses were 
proposed to explain this mismatch: (1) fast absorption of the 
lyophilizate, potentially missing a larger absorption peak or 
(2) occurrence of two absorption peaks. To confirm one of 
these hypotheses, Dossche et al. performed a clinical PK/PD 
study in children applying a rich sampling design during the 
absorption phase. In this study, the double absorption peak 
was confirmed in growing children (6 months to 8 years 
of age, especially 60 and 120 µg lyophilizate). Moreover, 
Michelet et al. [17] reanalyzed their previously published 
pediatric PK/PD model including the newly generated clini-
cal data, which resolved the previous stated discrepancy and 
confirmed the double absorption peak hypothesis.
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Pharmacology of Desmopressin in Children With Enuresis
Rittig et al. [36] investigated the effect of food intake on 
the absorption after PO administration of 400 µg desmopres-
sin to healthy adults aged 20–35 years. Concomitant admin-
istration of desmopressin and a standard meal (2199 kJ, Big 
 Mac®) and administration of desmopressin 1.5 h after eat-
ing a standard meal resulted in a reduced (50% lower Cmax) 
and delayed absorption (longer Tlag and higher Tmax with 
an increase from 0.25 h to 0.5 h and 1 h to 1.5 h, respec-
tively) in comparison with fasted patients. These observa-
tions were confirmed in a more recent study performed in 
Chinese healthy adults aged 18–45 years [63]. Two possible 
explanations were proposed for these observations: (1) the 
binding of desmopressin to food particles or (2) the interac-
tion of food with intestinal metabolic activity (increase in 
peptidase production). Michelet et al. [15] pooled pediatric 
data from two PK desmopressin trials in children and devel-
oped a model using a population PK approach on a sparse 
sampling set to understand the effect of food intake on the 
absorption of desmopressin (120 µg lyophilizate and 200 µg 
tablet). The effect of concomitant food intake was found to 
be clinically significant and might influence the bioavailabil-
ity and therefore the optimal dosing of desmopressin [17]. 
The latter was confirmed in another analysis, with the addi-
tion of lyophilizate data generated in the recently performed 
study of Dossche et al. in fasted younger children.
Callréus et al. [64] investigated the effect of the gastro-
intestinal motility and gastrointestinal secretion by admin-
istering erythromycin (increasing motility, 250 mg every 
6 h, first dose 3 days before the study and last dose at − 1 h) 
and loperamide (slowing motility, 4  mg, − 24  h, − 12  h 
and − 1 h) prior to PO administration of 400 µg desmo-
pressin to healthy volunteers (23–45 years). A significant 
increase in Cmax and Tmax was observed when desmopres-
sin was administered after pre-treatment with loperamide, 
while no significant difference in absorption was observed 
with erythromycin. The latter observations still need to be 
confirmed in the pediatric population.
5.2  Distribution
The volume of distribution (Vd) of desmopressin after IV 
injection is 28.2 L in 22- to 46-year-old subjects and 11.2 L 
in 55- to 75-year-old subjects [65, 66]. In children aged 
6–12 years, the mean population PK estimate of apparent 
Vd after administration of an oral lyophilizate was 8510 L, 
which would correspond to a systemic Vd of 21.3 L (assum-
ing 0.25% bioavailability) [13]. This result was in accordance 
with the result (8237 L) obtained by Michelet et al. [15]. The 
latter authors also observed an effect of body weight on Vd, 
indicating that dose adjustment might be required. Informa-
tion about the plasma protein binding of desmopressin is 
rather scarce. Lawton and Witty [19] mentioned that 50% 
of the absorbed desmopressin binds to plasma proteins. 
Desmopressin does not cross the blood–brain barrier after 
IV administration to patients aged 36–72 years [67]. Burrow 
et al. [68] determined desmopressin concentrations in breast 
milk in a 23-year-old woman with diabetes insipidus. They 
concluded that desmopressin seems to be a safe therapy, 
since only traces of desmopressin (max. 7 ng/L at 40 min 
post-administration) were found in breast milk. However, it 
should be noted that this study was only performed in one 
patient, so additional studies are required.
5.3  Metabolism
An in vitro study in rats demonstrated that 20% of desmo-
pressin was inactivated by the liver and only a small fraction 
by the kidney [69]. Fjellstad-Paulsen and Lundin [70] deter-
mined the degradation of AVP and desmopressin in human 
renal microvilli brush-border membranes and human liver 
membranes. Arginine vasopressin was found to be degraded 
in the kidney at both the C- and N-terminus as well as by 
disulphide cleavage when the cofactor glutathione was pre-
sent, and was found to be stable without this cofactor. How-
ever, degradation of desmopressin in the kidney was negligi-
ble even when glutathione was present. No degradation was 
observed when desmopressin was incubated with purified 
liver cell membranes, since desmopressin might undergo 
receptor-mediated endocytosis followed by intracellular 
metabolism. This theory was also supported by Lundin et al. 
[71], where rapid removal of desmopressin from the incuba-
tion medium was observed after incubation of desmopressin 
with liver tissue slices. Removal can be a consequence of 
binding to hepatic vasopressin receptors or internalization 
followed by intracellular degradation. Enzyme-dependent 
proteolysis of desmopressin by pancreatic enzymes in jeju-
nal and ileal juice also occur. Degradation of desmopres-
sin appears slower in jejunal than ileal juice; since it is pH 
dependent, it is more stable at acidic pH [72]. To confirm the 
theory of enzyme-dependent proteolysis of desmopressin, 
concomitant administration of aprotinin (broad-spectrum 
proteinase inhibitor) and desmopressin was studied. A con-
centration-dependent inhibition of desmopressin degradation 
was indeed observed, enhancing the bioavailability of orally 
administered desmopressin [73].
5.4  Excretion
The mean population PK values of apparent clearance for 
children (6–12 years) and adults (18–54 years) was 2330 L/h 
and 2930 L/h, respectively [13, 15]. The main route of elimi-
nation of desmopressin is renal excretion. Fjellstad-Paulsen 
et al. [61] determined the urinary excretion after IN, subcu-
taneous (SC) and PO administration (IN: 20 µg; SC: 2 µg; 
PO: 200 µg) in healthy adults aged 20–57 years. Forty-eight 
percent, 92% and 65% of the amount absorbed after SC, IN 
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and PO administration, respectively, was excreted in urine 
within 24 h. However, the renal fraction in the pediatric 
population still needs to be determined. The renal fraction 
of desmopressin after IV administration (4 µg) was 39% 
[74]. Moreover, Agerso et al. [74] investigated the corre-
lation between creatinine clearance and renal clearance in 
both healthy volunteers and renally impaired patients (aged 
49–68 years) and found that both renal and non-renal excre-
tion of intravenous desmopressin varied with creatinine 
clearance. A decrease of 1.67% in creatinine clearance led 
to a 1.74% decrease in renal clearance and a 0.93% decrease 
in nonrenal clearance of desmopressin. This observation 
could possibly be attributed to the association of renal 
impairment and a decrease in hepatic metabolism. Moreo-
ver, a prolongation of the elimination half-life (T½el) was 
observed. Since desmopressin is only partially eliminated 
(39%) by the kidney, the total clearance of desmopressin is 
less affected by renal function. Consequently, desmopressin 
is still well tolerated in renally impaired patients. However, 
when administering high doses of desmopressin, adverse 
effects may occur in those patients, so great caution should 
be exercised when establishing the exact dosing regimen. 
Lundin et al. [71] determined the excretion of desmopressin 
in bile after various routes of administration (intraduodenal, 
intrajugular and intraportal) in one conscious pig (Swed-
ish Landrace, 4 months old). Only low concentrations of 
desmopressin were retrieved in bile, < 1% of the available 
dose. The T½el after PO administration of desmopressin is 
prolonged in comparison with endogenous AVP, since its 
enzymatic degradation in liver and kidney are slower [75].
6  Pharmacodynamics
About 6–10% of children aged 7–8 years suffer from bed-
wetting; however, only 60–70% are responders (complete 
or partial responders) to desmopressin treatment [84–86]. 
Despite the low oral bioavailability, the plasma concentra-
tions are sufficient to achieve antidiuretic effects. This can 
be attributed to high receptor affinity and binding capacity of 
desmopressin to the V2 receptor [19]. Ideally, the duration of 
action of desmopressin for treating bedwetting should vary 
between 8 and 11 h, since longer durations could induce 
adverse effects (hyponatremia, seizures and abdominal pain). 
Multiple studies demonstrated the efficacy (reducing the 
number of wet incidents, reducing 24-h urine production) 
of the different desmopressin formulations in children with 
enuresis [87–93].
6.1  Formulation Effect
Various formulations of desmopressin have been used to 
treat bedwetting. De Guchtenaere et al. [94] compared an 
oral lyophilizate tablet (120 µg) with a conventional tablet 
(200 µg) in children aged 12.1 ± 2.5 years (enuresis) and 
concluded that the lyophilizate has a higher concentrat-
ing capacity and requires a shorter time to reach maximal 
effect in comparison with the tablet. De Bruyne et al. [14] 
performed a relative bioavailability study of a 200-µg tab-
let compared with a 120-µg lyophilizate in children aged 
5–18 years (enuresis). Relative bioavailability between both 
formulations was found, but the smaller inter- and intra-sub-
ject variability in plasma concentration and better predict-
ability of plasma concentrations makes the lyophilizate more 
reliable in comparison with the tablet. However, Michelet 
et al. [15] constructed a population PK model based on 
pooled data from the studies of Osterberg et al. [13] and 
De Bruyne et al. [14], whereby the claimed bioequivalence 
between the two formulations in adults (200-µg tablet and 
120-µg lyophilizate) could not be extrapolated to children. 
Moreover, in a follow-up modeling study, after inclusion 
of the data generated by Dossche et al., Michelet et al. [17] 
found that bioequivalence of the two formulations could not 
be claimed in children due to differences in absorption and 
the impact of food and age (0.5–16 years). Lottman et al. 
[95] also compared efficacy and safety between the lyophi-
lizate (120–240 µg) and the tablet (200–400 µg) in children 
(5–15 years) with enuresis. Both formulations were well tol-
erated and no adverse effects related to the study treatment 
were observed. The incidence of enuresis events measured 
during a 6-week cross-over study (3 weeks formulation one 
[tablet or lyophilizate] followed by 3 weeks formulation two 
[lyophilizate or tablet]) was comparable between both for-
mulations. Higher compliance was achieved with the lyo-
philizate, since it circumvents the difficulties observed when 
children need to swallow desmopressin tablets. The latter 
was also confirmed by Juul et al. [96], whereby a higher 
patient compliance and consequently increased treatment 
outcome was observed with the lyophilizate (5–15 years, 
enuresis). Rembratt et al. [66] determined the PD param-
eters of desmopressin (PO: 200 µg; IV: 2 µg) and the influ-
ence of the circadian rhythm on those parameters in male 
patients aged 55–75 years (high incidence of nocturia). The 
PD effects were almost identical for both formulations dur-
ing the first 6 h; however, the duration of action of the IV 
administration lasted longer. When the PD parameters of 
desmopressin administration during daytime or nighttime 
are compared, the effects on urine production and osmolal-
ity were prolonged to 12 h at nighttime, possibly due to the 
additive effect of desmopressin and endogenous vasopressin 
at night. This observation should also be evaluated in the 
pediatric population.
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6.2  Dose–Effect
Schulman et al. [22] performed an 8-week dose titration 
study with a desmopressin tablet in children with bedwetting 
(aged 6–16 years). The starting dose was set at 200 µg, fol-
lowed by an increase in 200-µg increments (evaluation every 
2 weeks) until dryness or the maximum dose of 600 µg was 
achieved. A linear dose–response relationship was noted, 
meaning that the reduction in the number of wet nights per 
2 weeks (number of nights reduced by 50% compared with 
the baseline) is linearly related to the administered desmo-
pressin dose.
Vande Walle et al. [37] performed one of the first dose-
titration studies (30, 60, 120, 240, 360 and 480 µg) of 
desmopressin lyophilizate to assess the PD measurements 
in enuretic children aged 6–12 years (urinary volume, osmo-
lality and duration of action). A decline in urinary output 
and maximum osmolality (> 800 mOsm/kg bodyweight) was 
observed 1 h post-administration for the 60- to 480-µg dos-
ing. Maximum effect of the 30-µg dose was also achieved 
after 1 h, but maximum osmolality was lower in comparison 
with the other doses. Since the maximum effect is reached 
1 h after dosing, it is important to administer the lyophilizate 
1 h prior to bedtime. The duration of action is around 6 h 
for 120 µg and > 8 h for > 120-µg doses, enabling control of 
diuresis for 7–11 h (≈ approximately one night). Since the 
maximum osmolality, duration of action and urinary output 
are comparable between the 240-, 360- and 480-µg doses 
and most enuresis events occur during the first 2 h of sleep 
[97], a dose range of 120–240 µg should be sufficient. The 
lower doses also reduce the risk of adverse effects. Ferrara 
et al. [98] performed a 9-week dose titration study with a 
desmopressin lyophilizate in children with enuresis (aged 
5–18 years), followed by an observation period of 3 months 
(responders). The starting dose was set at 120 µg, followed 
by an increase to 180 µg (partial responders at 120 µg, 
evaluation after 3 weeks) and 240 µg (partial responders 
at 180 µg, evaluation after 3 weeks). The non-responders 
were excluded from the study. In this study, only a limited 
number of patients had a further improvement of symptoms 
(14.3%) or were complete responders (9.5%) after titrating 
the dose to 180 µg. No improvement of the symptoms was 
observed when the dose was further titrated to 240 µg, which 
demonstrates the need to prescribe the right dose to the right 
patient. Michelet et al. [17] evaluated if the current standard 
dosing regimens (120 µg) were sufficient for children who 
were not fasted when taking desmopressin before bedtime. 
The authors concluded that the current dosing using lyo-
philizate was inappropriate, whereby new and simple simu-
lated dosing schemes based on age or weight were proposed 
(age based: 30 µg [< 2 years], 60 µg [2–4 years], 120 µg 
[4–8 years], 180 µg [8–12 years], 240 µg [+ 12 years]; 
weight based: 45 µg [< 12.5 kg], 90 µg [12.5–25 kg], 180 µg 
[25–50 kg], 360 µg [50–100 kg]).
6.3  Food Effect
Rittig et al. [36] investigated the effect of food intake on the 
antidiuretic action of desmopressin after PO administration 
of two 200-µg tablets to healthy adults aged 20–35 years. 
Despite the reduced and delayed absorption of desmopres-
sin, concomitant administration of a standard meal and 
desmopressin did not significantly alter the antidiuretic 
response to desmopressin 400 µg during the first 4 h post-
administration. However, the duration of action was pro-
longed in fasted pediatric patients in comparison with fed 
pediatric patients, since the plasma drug concentrations were 
significantly higher [17].
6.4  Predictors of Response
An anti-enuretic response, namely a reduction in number of 
wet nights of 100% (complete responder) or of 50–99% (par-
tial responder), is achieved in 60–70% of the children treated 
with desmopressin [25, 35, 99]. Thirty to forty percent of 
the patients are non-responders, probably attributed to small 
nocturnal bladder capacity and detrusor-dependent nocturnal 
enuresis. Despite the proven success rate, a high relapse rate 
(78%) after short-term desmopressin treatment is observed, 
whereas the relapse rate was decreased when administration 
was maintained for longer [35]. The high relapse rate and the 
number of non-responders render it necessary to use a prag-
matic approach for the treatment of bedwetting, whereby 
careful consideration of the position of desmopressin within 
this treatment is required.
Different underlying pathophysiological mechanisms of 
enuresis could explain the differences in response to desmo-
pressin [100]. An anti-enuretic response of desmopressin 
is expected when patients are able to increase their urinary 
osmolality [11]. Nevéus et al. [58] studied the difference 
in PD effects after IV injection of desmopressin (2 mg) to 
children aged 7.6 and 16.2 years (enuresis). Half of the study 
population (n = 6) were responders and half (n = 6) were 
non-responders to the treatment. Enuresis only occurred in 
the non-responder group. It appears that in both respond-
ers and non-responders a low nocturnal urine production 
and high morning urine osmolality was present. A higher 
urinary output of less concentrated urine was produced by 
the responders, whereas non-responders voided with smaller 
bladder volumes. The latter is probably due to instability 
of the bladder. Rushton et al. [101] evaluated if maximum 
functional bladder capacity (as a percent of predicted blad-
der capacity) could predict response to desmopressin in 
enuretic children aged 8–14 years. The authors observed that 
when the maximum functional bladder capacity exceeded 
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the mean capacity of the studied patients (= 70% of the age 
predicted capacity), the likelihood of response increased 
twofold. Hogg and Husmann [102] found that there was a 
good correlation (91%) between successful therapy response 
to desmopressin and a positive familial nocturnal enuresis 
history, whereas a poor correlation was noted when the fam-
ily history was negative (7%). The latter was in contrast to 
the results found by Schaumburg et al. [103], where success-
ful therapeutic response could not be predicted by a posi-
tive family history. Devitt et al. [104] investigated the rela-
tionship between nocturnal concentrations of AVP and the 
response to desmopressin, which combined with physiologi-
cal factors might predict a successful response. The authors 
observed a correlation between response to desmopressin 
and nocturnal AVP concentrations, which is influenced by 
neuronal patterning during early infancy (maturation of neu-
ronal networks involving the hypothalamic pituitary axis and 
AVP production). The best predictive physiological factors 
were (1) breast feeding; (2) mean nocturnal AVP concen-
tration and (iii) height. Moreover, an inverse correlation 
with low birth weight and poor linear growth was noted. 
Kruse et al. [105] evaluated predictive factors (age, gender, 
heredity, sleep pattern, previous treatments, number of wet 
incidents and dosing regimens) for successful desmopressin 
treatment (6–12 years, MNE). No specific predictors could 
be identified, possibly because the pathology of enuresis 
needs to be considered to evaluate the predictors and the 
success rate of the therapy. Van Herzeele et al. [106] also 
evaluated predictive parameters for desmopressin response 
(number of wet nights a week, fluid intake, daytime voiding 
frequency, diuresis, age, body mass index, country, family 
history and sex), whereby only nocturnal diuresis volume 
(volume of 180, 300, 400 mL: 11%, 20%, 60% complete 
responders, respectively) and the number of wet nights a 
week (limited number increases response rate) were con-
sidered good predictors (aged 5–15 years, enuresis). When 
looking at the demographic variables, only age was consid-
ered significant; the response rate in younger children was 
significantly lower than in adolescents. Van Herzeele et al. 
[107] also evaluated if the patient’s motivation and com-
pliance can influence the response rate. The compliance in 
723 children treated with desmopressin tablets for 6 months 
or less was determined and the authors concluded that a 
decreased compliance was related to a lower response rate.
The PD response of desmopressin is different between 
male and female patients, with a higher antidiuretic efficacy 
observed in adult females [12, 65]. Juul et al. [108] exam-
ined the sex difference in antidiuretic response in patients 
with nocturia (> 2 voids/night and serum sodium concen-
tration > 135 mmol/L) and healthy volunteers. The mean 
decrease in nocturnal urine volume was higher in females 
than males. Moreover, the decrease in sodium plasma 
concentrations was more profound in females, potentially 
causing hyponatremia in those patients, whereby a narrower 
therapeutic window should be applied. The exact mecha-
nisms to explain those differences are still unidentified, 
but different expression of the  V2 receptor in males versus 
females could be a possible explanation. Liu et al. [109] 
examined the expression of  V2 receptor mRNA and protein 
in kidneys of female and male Sprague–Dawley rats, and 
linked the dimorphic traits between the sexes and pheno-
typic variability among female heterozygotes to the second 
‘silenced’ X-chromosome. Some genes escape the inactiva-
tion of the second X-chromosome, whereby a variability in 
gene expression could be observed. Carrel and Willard [110] 
demonstrated that the  V2 receptor has a high probability to 
escape inactivation, potentially leading to expression of 
this gene from both X-chromosomes in females. However, 
further research is required to completely understand the 
sex differences in antidiuretic response of desmopressin. 
Schroeder et al. [111] determined if there were sex-related 
differences in renal sensitivity to desmopressin in Danish 
children with nocturnal enuresis (mean age 9.2 years). In 
this study, a greater percentage of girls than boys had a long-
term effect of the lowest desmopressin lyophilizate dose, 
confirming the theory that girls could possibly be more 
sensitive to desmopressin than boys. However, the authors 
noted that the difference between girls and boys was rather 
small, necessitating additional studies to further confirm this 
theory. When administering the tablet and the nasal spray, no 
sex-related differences were observed, possibly attributed to 
the fact that sex differences were only observed at the low-
est desmopressin doses, as the doses of the tablet and the 
nasal spray were high. For both boys and girls, no hospital 
diagnoses of hyponatremia were documented for any of the 
mentioned formulations.
7  Adverse Events
The safety of different desmopressin formulations has been 
thoroughly researched. The use of desmopressin is con-
sidered safe but additional preventive measures should be 
taken in order to prevent severe hyponatremia. In 1987, 
Fjellstad-Paulsen et al. [112] compared the tolerability of IN 
and PO desmopressin administration in children with enu-
resis (aged 6–14 years) and did not observe any significant 
adverse events related to these formulations (two patients 
experienced nasal discomfort and three patients experienced 
epistaxis). Li Volti et al. [113] and Akoğlu et al. [114] did 
not observe any effect on nasal cytology and mucociliary 
clearance after 6 months of nasal spray therapy in children 
aged 6–16 years. Desmopressin does not affect sleep directly, 
but responders exhibit more rapid-eye-movement sleep than 
non-responders, which might be caused by differences in 
vasopressin secretion [115]. Dehoorne et al. [116] evaluated 
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clinical symptoms of water intoxication after administra-
tion of desmopressin nasal spray to 2043 pediatric patients 
(1999–2004). Fifteen children (aged 6–15 years) were iden-
tified to have water intoxication resulting in vomiting, head-
ache, decreased consciousness, seizures and hyponatremia. 
The authors concluded that these symptoms were secondary 
to a prolonged desmopressin bioactivity, that is, prolonged 
maximal urinary concentration capacity and delayed resto-
ration of daytime diluting. Moreover, Glazener and Evans 
[99] found 21 case reports of water intoxication (< 1,993), 
probably due to over-drinking at bedtime, as a maximum 
concomitant fluid intake during the night of 200–240 mL 
was recommended. The latter is also confirmed by Thum-
fart et al. [117], Vande Walle et al. [9], Lucchini et al. [118] 
and Kamperis et al. [34]. Del Gado et al. [119] evaluated 
the safety of desmopressin using either the nasal spray or 
the tablet (initial dose: 20 µg; maximum dose: 40 µg). Only 
transient, mild side effects were observed. Kano and Ari-
saka [120] administered desmopressin nasal spray (10 µg, 
uptitrated to 20 µg when patients remained incontinent after 
4 weeks) for long-term treatment (between 12 and 24 weeks) 
of children (aged 6–15 years) diagnosed with enuresis. The 
authors did not observe any significant adverse effects (one 
patient had acute rhinitis and one patient had an event of 
excitement) and concluded that the nasal spray is safe and 
effective for long-term treatment in children with enuresis. 
The latter was also concluded in the studies performed by 
Knudsen et al. (MNE [121]), Hjälmås et al. (MNE [88]) 
and Läckgren et  al. (refractory enuresis [89]). Alloussi 
et al. [122] reviewed 99 studies (7422 patients, children 
aged > 5 years to adolescents), whereby a low number of 
case reports [123–125] and post-marketing safety data dem-
onstrated a higher risk of hyponatremia when administering 
nasal formulations. Despite the fact that hyponatremia events 
are rather rare, the authors made a plea for safety analysis, 
and not only limited to nasal formulations, by using routine 
laboratory testing. In comparison with IN administration, 
PO administration has a decreased risk of hyponatremia. 
Robson et  al. [10] determined potential risk factors for 
hyponatremia: (1) excessive fluid intake, (2) overdosing, 
(3) age (< 6 years) and (4) interactions with other drugs. 
Van Herzeele et al. [126] performed a prospective study to 
determine the safety of desmopressin tablets in 744 children 
with bedwetting (aged 5–15 years), whereby no drug-related 
adverse events were observed. Ferrara et al. [127] included 
237 enuretic children (5–18 years) to determine the adverse 
events of the lyophilizate based on their personal experience. 
Twenty-two children reported mild transient adverse events. 
This study demonstrated that the lyophilizate is safe to treat 
children with enuresis. Juul et al. [108] demonstrated a sex 
difference in incidence of hyponatremia in adults, whereby 
adaptation of the dose stratified by sex was required. For 
adult women, a dose of 25-µg lyophilizate is considered 
efficacious and safe, whereas for adult men this dose was 
50- to 100-µg lyophilizate. To date, the latter still needs to 
be determined in the pediatric population, since only non-
gender adapted doses (60- to 360-µg lyophilizate) were pro-
posed in this population.
8  Conclusion
For more than 40 years, desmopressin has been mostly pre-
scribed to children (approximately 90%) and investigated 
in adults. Despite the fact that desmopressin is generally 
accepted for the treatment of children with enuresis, there 
are still a lot of research questions that need to be addressed 
concerning the pharmacology of desmopressin in the pedi-
atric population. The current review summarized the avail-
able literature concerning this topic, whereby the need for 
additional PK/PD studies in children was demonstrated. The 
following research questions remain:
• Double absorption peak Due to the rich sampling strat-
egy applied in a recent study (Dossche et al.), a double 
absorption peak was observed in the plasma concentra-
tion–time profiles of the younger children administered 
a lyophilizate (aged 6 months to 8 years). Further studies 
are required to determine the clinical relevance (efficacy 
and safety) of this double absorption peak.
• Food effect A profound food effect on oral bioavailability 
was demonstrated, necessitating administration of desm-
opressin without concomitant food ingestion. The latter 
is rather difficult to achieve in younger children, though 
a dose regimen adaptation can be considered. However, 
the fed patients were older than 8 years of age and the 
young fasted patients only received a lyophilizate. Conse-
quently, the food effect should be confirmed in fed young 
patients and fasted young patients receiving a tablet as 
well.
• Bioequivalence and therapeutic equivalence The claimed 
equivalence in adults (120-µg lyophilizate and 200-µg 
tablet) cannot just be extrapolated to children based 
on data obtained from clinical trials in adults alone. 
Observed differences in absorption of both formulations 
is probably attributed to a food and maturation effect. 
However, to be able to compare these formulations thor-
oughly, acquiring additional data (cfr. section double 
absorption peak and food effect) is required.
• Dosing regimen At the moment, flat dose regimens for 
the lyophilizate (60–480 µg) are applied for all chil-
dren. However, these dosing regimens might not be 
appropriate since the target attainment is only 33.4%, 
resulting in suboptimal or too prolonged effects. It might 
be more appropriate to use bodyweight (< 4 years) or 
age-dependent (> 4 years) dose regimens as proposed 
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by Michelet et al. [17]. These proposed dose regimens 
should be tested in a follow-up clinical trial, whereby 
the PD response measured by biomarkers (i.e. baseline 
urine osmolality, diuresis or aquaporin levels) should be 
considered. The same exercise should be performed for 
the tablet formulation. Moreover, in these trials, dose 
stratification by gender should be considered.
• Study endpoints In future studies it might be helpful to 
evaluate both anti-diuretic and anti-enuretic effect by 
performing a 1-day intensive PK/PD sampling, followed 
by the registration of the number of wet nights and diu-
resis in the following 14 days. The change or reduction 
of number of wet nights and the PK/PD of both formula-
tions might be linked using, for example, time-to-event 
modeling.
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